secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2022-08-26T23:59:59+00:00
Accession:  0001437749-22-021377
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions appoints Timothy L. Moore to board of directors effective Sept 1, 2022
--------------------------------------------------------------------------------

- Moore brings 30+ years biopharma ops experience; served as EVP Technical Ops at Kite Pharma (Gilead) and head of Genentech biologics ops.
- Moore also serves on Cerus Corporation (CERS) board.
- Appointed to Compensation Committee and Nominating and Governance Committee.
- Board expands to six members; Moore qualifies as independent under Nasdaq rules.
- No related-party transactions requiring disclosure; compensation same as other non-employee directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000143774922021377/0001437749-22-021377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000143774922021377/bioli20220825_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-021377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer